Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Breast Cancer

  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 29 articles:
HTML format

Single Articles

    May 2020
  1. MURRAY BRUNT A, Haviland JS, Wheatley DA, Sydenham MA, et al
    Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
    Lancet. 2020;395:1613-1626.
    PubMed     Abstract available

    March 2020
  2. SPRING LM, Wander SA, Andre F, Moy B, et al
    Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
    Lancet. 2020;395:817-827.
    PubMed     Abstract available

    February 2020
  3. EARL HM, Hiller L, Plummer C, Miles D, et al
    Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply.
    Lancet. 2020;395:492-493.

  4. GUO S, Tse G, Liu T
    Protective strategies to prevent trastuzumab-induced cardiotoxicity.
    Lancet. 2020;395:491-492.

  5. LANE R
    Geraldine McGinty: leading light in US radiology.
    Lancet. 2020;395:407.

    January 2020
  6. CHUMSRI S, Thompson EA
    Carryover effects of aromatase inhibitors in prevention.
    Lancet. 2020;395:91-92.

    Biosimilars: a new era in access to breast cancer treatment.
    Lancet. 2020;395:2.

    December 2019
  8. COLES CE, Bliss JM, Poortmans PM
    Accelerated partial breast irradiation: more questions than answers?
    Lancet. 2019;394:2127-2129.

  9. CUZICK J, Sestak I, Forbes JF, Dowsett M, et al
    Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
    Lancet. 2019 Dec 11. pii: S0140-6736(19)32955.
    PubMed     Abstract available

  10. VICINI FA, Cecchini RS, White JR, Arthur DW, et al
    Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
    Lancet. 2019 Dec 5. pii: S0140-6736(19)32514.
    PubMed     Abstract available

  11. WHELAN TJ, Julian JA, Berrang TS, Kim DH, et al
    External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
    Lancet. 2019 Dec 5. pii: S0140-6736(19)32515.
    PubMed     Abstract available

    October 2019
  12. SESSLER DI, Pei L, Huang Y, Fleischmann E, et al
    Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial.
    Lancet. 2019 Oct 18. pii: S0140-6736(19)32313.
    PubMed     Abstract available

  13. ABDALLAH FW, Wijeysundera DN
    Anaesthetic interventions and long-term tumour recurrence.
    Lancet. 2019 Oct 18. pii: S0140-6736(19)32314.

    August 2019
    Menopausal hormones: definitive evidence for breast cancer.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)31901.

  15. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)31709.
    PubMed     Abstract available

  16. BERAL V, Peto R, Pirie K, Reeves G, et al
    Menopausal hormone therapy and 20-year breast cancer mortality.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)32033.

    June 2019
    Is the duration of adjuvant trastuzumab debate still clinically relevant?
    Lancet. 2019;393:2565-2567.

  18. PIVOT X, Romieu G, Debled M, Pierga JY, et al
    6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
    Lancet. 2019 Jun 6. pii: S0140-6736(19)30653.
    PubMed     Abstract available

  19. EARL HM, Hiller L, Vallier AL, Loi S, et al
    6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
    Lancet. 2019 Jun 6. pii: S0140-6736(19)30650.
    PubMed     Abstract available

    February 2019
  20. MUTEBI M
    Africa rising: gendered journeys of women patients and providers.
    Lancet. 2019;393:517-518.

    Dose intensification of chemotherapy for early breast cancer in the age of de-escalation.
    Lancet. 2019 Feb 7. pii: S0140-6736(19)30197.

  22. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
    Lancet. 2019 Feb 7. pii: S0140-6736(18)33137.
    PubMed     Abstract available

    December 2018
  23. LEVY A, Chargari C, Deutsch E, Rivera S, et al
    Concerns about cardiotoxicity in the HERA trial.
    Lancet. 2018;390:2767.

  24. CAMERON DA, Gelber RD, Procter M, Suter T, et al
    Concerns about cardiotoxicity in the HERA trial - Authors' reply.
    Lancet. 2018;390:2767-2768.

    August 2018
  25. WILLER H
    Breast cancer in Venezuela: back to the 20th century.
    Lancet. 2018;392:461-462.

    June 2018
  26. SHEIKH S, Sasieni P
    When should the errors in the UK's breast screening programme have been spotted?
    Lancet. 2018;391:2319-2320.

    February 2018
  27. MCPHERSON K, Al Waheidi S
    The overestimation and the inappropriate promotion of the benefits of mammographic screening in breast cancer research and interventions in the Gaza Strip.
    Lancet. 2018;391 Suppl 2:S21.
    PubMed     Abstract available

    January 2018
  28. COLES CE, Haviland JS, Kirby AM, Titley J, et al
    Targeted radiotherapy for early breast cancer - Authors' reply.
    Lancet. 2018;391:27-28.

  29. VAIDYA JS, Bulsara M, Wenz F, Tobias JS, et al
    Targeted radiotherapy for early breast cancer.
    Lancet. 2018;391:26-27.

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.